BlossomHill Therapeutics, Inc.
BLSMDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
Get an email about BLSM's next catalysts
Track BlossomHill Therapeutics (BLSM) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
BH-30643
NSCLC (Advanced Non-small Cell Lung Cancer)
BH-30643 combo therapy with Carboplatin/Pemetrexed
NSCLC (Advanced Non-small Cell Lung Cancer)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
BH-30643 | Phase 2 | NSCLC (Advanced Non-small Cell Lung Cancer) | - | - |
BH-30643 combo therapy with Carboplatin/Pemetrexed | Phase 2 | NSCLC (Advanced Non-small Cell Lung Cancer) | - | - |
Frequently asked questions
What is in BlossomHill Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in BlossomHill Therapeutics, Inc.'s (BLSM) pipeline across Phase 2. Its lead program is BH-30643 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BlossomHill Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for BlossomHill Therapeutics, Inc. (BLSM) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track BLSM biotech catalysts?→
Add BLSM to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BlossomHill Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.